Response to treatment in patients with multiple myeloma: PET/CT imaging with [68Ga]Ga-Pentixafor

Zusammenfassung der Studie

In the presence of multiple myeloma, the standard examination at the time of diagnosis consists of performing PET/CT imaging with the FDG molecule and monitoring through blood parameters. Unfortunately, the FDG tracer can have some disadvantages, such as not visualizing certain lesions in the bones. Monitoring the disease through blood parameters can also provide false reassurance in cases of locally active disease. The aim of this study is to perform PET/CT imaging with a molecule called [68Ga]Ga-PentixaFor, in order to measure the activity of this disease through imaging, compare this activity to what can be measured in the blood, and evaluate the advantages of [68Ga]Ga-PentixaFor compared to PET/CT using FDG. The goal is to perform imaging before the initiation of myeloma treatment (or before a new treatment in case of relapse), and then after 8 to 12 weeks of treatment for disease monitoring.

(BASEC)

Untersuchte Intervention

2 PET/CT scans with the research molecule [68Ga]Ga-PentixaFor (investigation #1 at the start and then investigation #2 at 8-12 weeks). This examination lasts about 15 – 20 minutes. In total, the patient spends about 2 hours in the nuclear medicine department.

(BASEC)

Untersuchte Krankheit(en)

Multiple myeloma

(BASEC)

Sponsor

Prof. Dr. Niklaus Schaefer, Nuclear Medicine Service, CHUV, Lausanne

(BASEC)

Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)

Ethikkommission Waadt

(BASEC)

Datum der Bewilligung durch die Ethikkommission

24.02.2025

(BASEC)

Ergebnisse der Studie